IN DEPTH

3D printing devices on site: healthcare hero or hazard?

Medical devices for rare diseases: the unmet need

REGULATION

Lessons learned from Theranos

Will the fall of Theranos become a wake-up call for regulation in the lab-developed test market?

REGULATION

UK med tech faces regulatory uncertainty post-Brexit

AI

How AI could help improve clinical trial diversity

3D printing devices on site: healthcare hero or hazard?

Medical devices for rare diseases: the unmet need

05/22/2024 21:09:27
  • Home | The Theranos saga
  • In this issue
  • Contents
  • Formacoat Company Insight
  • Formacoat
  • PAMA Manufacturing and Sterilization
  • Briefing
  • Industry news
  • The medical industry briefing
  • Covid-19 executive briefing by GlobalData
  • Sartorius
  • Comment
  • 3D printing will languish in healthcare – until it explodes
  • Public healthcare systems will be last in line for surgical robotic systems
  • The pandemic has increased the use of virtual application services
  • Sandvik Company Insight
  • Sandvik
  • In Depth
  • The Theranos saga: a wake-up call for the lab-developed test market
  • Medical devices for rare diseases: the unmet need
  • 3D printing devices on site: healthcare hero or hazard?
  • IQVIA on AI’s potential to match patients to trials and improve trial diversity
  • UK med tech faces regulatory uncertainty post-Brexit
  • In Data
  • The medical devices companies leading the way in cybersecurity
  • Internet of things innovation is declining
  • Europe is seeing a hiring boom in data analytics
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Events
  • Next Issue
01/31/2022 00:00:00